



IDWeek Update (as of 9/28/18)

Copyright, Disclaimer, and Related Policies

All materials included on the IDWeek website and/or audio media are subject to copyrights owned by IDSA, SHEA, HIVMA, and PIDS or other individuals or entities. Any reproduction, retransmission or republication of all or part of any document is strictly prohibited, unless the copyright owner of the material has expressly granted its prior written consent to so reproduce, retransmit or republish the material. All other rights reserved.

Abstracts

Abstracts are available electronically on the IDWeek Interactive Program Planner. Visit www.idweek.org and under program, click on the “Interactive Program” to view the complete abstracts. Create your itinerary using the Interactive Program Tool and download abstracts to PDF. Abstracts are also available in the IDWeek Meeting App. Abstracts will also be available via OFID after IDWeek is over.

IDWeek Meeting Surveys and Claiming CME/CPE/MOC Credit

IDWeek meeting surveys can be completed online after the meeting – watch your email for a link.

Individual session evaluations are completed online through the process of claiming CME/CPE/MOC credit. **The deadline to claim credit is November 26, 2018.** Visit www.idweek.org/post-meeting-tools for details about how to claim credit and complete session evaluations.

IDWeek Special Events

Don't miss out on these special IDWeek events!

Opening Reception and “Posters in the Park” Wednesday, October 3, 5:30 – 6:30 p.m., North Hall D Opening Reception Area

The IDWeek Opening Reception and the “Posters in the Park” event will be held together on Wednesday, October 3, from 5:30 - 6:30 p.m. in the North Hall D Opening Reception Area, immediately following the Opening Plenary Session. Mingle with colleagues and talk to poster presenters whose research has been specially selected by each of the partner societies. This event is open to all registered attendees.

SHEA President's Reception and Business Meeting Thursday, October 4, 5:45 – 6:30 p.m., Parc55, Embarcadero Room

Join SHEA Leadership for SHEA President's Reception & Business Meeting on Thursday, October 4 from 6 - 7:30 p.m. in the Embarcadero Room at the Parc 55 Hotel. SHEA's newly elected leadership will be announced along with a wrap up of SHEA's activities for the past year. SHEA will present the NEW SHEA Research Scholar Grant and the top fundraisers of the Race Against Resistance. Please join us for light refreshments as we discuss SHEA's successful year!

IDEa Incubator Thursday, October 4, 5 – 6 p.m., South Hall A

New in 2018 is the IDEa Incubator. Come and watch three finalists present their inventions, products, or devices for a chance at a \$10,000 prize! The finalists will present their ideas in front of an expert panel of judges from the business, technology, and medical industries.

Career Networking Event Thursday, October 4, 6 – 8 p.m., North Lower Lobby

Top employers from across the nation will come together with qualified infectious diseases specialists seeking employment. Participating companies represent a variety of practice types, with positions ranging from novice to experienced clinicians, all looking to hire infectious diseases specialists.

PIDS Business Meeting Thursday, October 4, 6 – 7:30 p.m., N23

Join PIDS Leadership for the PIDS Business Meeting on Thursday, October 4 from 6 - 6:45 p.m. in the Moscone Center, North 23. Several PIDS Society Awards will be presented along with a wrap up from the year and a look forward at the year to come.

Cocktails and Conversation with CDC Director, Robert Redfield, MD, along with an IDSA and HIVMA update, "Reflecting the New Face of ID"

Friday, October 5, 5 – 6 p.m., North Hall D
Join IDSA and HIVMA leadership for a special session with CDC Director Robert Redfield, MD, on Friday, October 5, from 5 - 6 p.m. in North Hall D in the Moscone Center. Hear Dr. Redfield's perspective as a public leader actively engaged in clinical research and clinical care of chronic human viral infections and infectious diseases, especially HIV, for more than 30 years. In addition, hear an update from IDSA and HIVMA leadership on key projects in the works and successful accomplishments over the past year. Please join us for cocktails and to catch up with friends!

IDBugBowl

Saturday, October 6, 5 – 6 p.m., North Hall D

Come match your knowledge of ID Trivia with contestants from the Stanford, UCSF, Wake Forest, and University of Kansas ID programs! The teams will battle it out to see who comes out on top in the inaugural IDBugBowl.

Program and Abstract Updates

Session 2. Symposium

Late Breaker Infectious Disease Updates

Wednesday, October 3, 1:30 – 3:15 p.m.

- 1:** Recent Ebola Outbreaks in the Democratic Republic of Congo; Mary Choi, MD, MPH, Centers for Disease Control
- 2:** Integrating Research into Outbreak Response: Use of Investigational Ebola Vaccines and Therapeutics During Outbreaks in the Democratic Republic of Congo; Elizabeth Higgs, MD, National Institutes of Health
- 3:** Nipah Virus Returns; Christopher Broder, PhD, Uniformed Services University
- 4:** Recent Anthrax Outbreaks in Humans and Animals; Caitlin Cossaboom, MPH, DVM, PhD, Centers for Disease Control and Prevention

Session 48. Oral Abstract

Late Breaker Oral Abstracts: HIV and Antibiotic Trials

Thursday, October 4, 10:30 – 11:45 a.m.

- LB1:** Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
- LB2:** Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
- LB3:** Daptomycin plus Fosfomycin versus Daptomycin Monotherapy for Methicillin-resistant *Staphylococcus aureus* Bacteremia. A Multicenter, Randomized, Clinical Trial
- LB4:** A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs ABC/DTG/3TC in Treatment-Naïve Adults at Week 96
- LB5:** Safety of In Utero Antiretroviral (ARV) Exposure: Neurologic Outcomes in HIV-Exposed, Uninfected Children
- LB6:** Oral Lefamulin Is Safe and Effective in the Treatment of Adults with Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study

Session 120. Symposium

Late Breaker Outbreaks

Friday, October 5, 10:30 – 11:45 a.m.

- 951:** Nationwide Outbreak of Shiga-toxin Producing *E. Coli* Due to Romaine Lettuce; Christopher Braden, MD, Centers for Disease Control and Prevention
- 952:** Smorgasbord of 2018 Foodborne Outbreaks: Lessons Learned; Robert V. Tauxe, MD, MPH, FIDSA, Centers for Disease Control and Prevention
- 953:** Substance Use and ID Care: A View from San Francisco; Phillip Coffin, MD, MIA, San Francisco Department of Public Health

Session 167. Oral Abstract

Late Breaker Oral Abstracts: Emerging Infections

Friday, October 5, 2 – 3:15 p.m.

- LB7:** Contact Tracing Investigation Following First Case of Andes Virus in the United States
- LB8:** Outbreak of Enterovirus A71 Neurologic Disease in Children — Colorado, 2018
- LB9:** Rising High Rate of Invasive Group A *Streptococcus* Infections Among Persons Experiencing Homelessness in San Francisco, 2010–2017
- LB10:** Changing Epidemiology of Hepatitis A Virus Infections— United States, 2007–2017
- LB11:** LB11
Rapid Rise in Decreased Susceptibility to Azithromycin among *Shigella* Isolates in the United States: A Look at National Surveillance Data, 2011–2017
- LB12:** Safety and Efficacy of Fidaxomicin and Vancomycin in Pediatric Patients with *Clostridium difficile* Infection: Phase III, Multicenter, Investigator-blind, Randomized, Parallel Group (SUNSHINE) Study
- LB13:** *Candida auris* in NYC: A Health System's Experience Treating the Emerging Drug-Resistant Yeast

Session 213. Oral Abstract

Late Breaker Oral Abstracts: Influenza and Vaccines

Saturday, October 6, 10:30 – 11:45 a.m.

- LB14:** Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older
- LB15:** Vaccine Effectiveness of Flucelvax Relative to Inactivated Influenza Vaccine During the 2017-18 Influenza Season in Northern California
- LB16:** Phase 3 Trial of Baloxavir Marboxil in High Risk Influenza Patients (CAPSTONE-2 Study)
- LB17:** Age-related differences in influenza type/subtype among patients hospitalized with influenza, FluSurv-NET— 2017–2018
- LB18:** An Enveloped Virus-like Particle (eVLP) Cytomegalovirus (CMV) Vaccine is Immunogenic and Safe: Results of a First-in-Humans Study
- LB19:** Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants
- LB20:** Impact of School-Located Influenza Vaccination on Vaccination Coverage, School Absenteeism, and Influenza Hospitalization

Withdrawn Abstracts

Oral Abstract Presentations:

- 123.** Hansen's Disease and Complications Among Marshallese-Americans in Northwest Arkansas, 2003–2017
- 870.** Incidence and Temporality of Influenza-Related Parotitis — Arkansas, 2016–17

Poster Abstract Presentations:

- 542.** Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates
- 582.** Strengthening HIV Care and Treatment in the RoC Military
- 676.** A Retrospective Forensic Review of Sudden Unexpected Infectious Deaths

1078. Use of PCR/Electrospray Ionization Mass Spectrometry for Rapid Identification and Antibiotic Treatment Adaptation in Patients suffering from Infective Endocarditis

1080. Time to blood culture positivity in *Staphylococcus aureus* bacteremia is associated with the risk of infectious endocarditis

1341. ASN100-Mediated Neutralization of *Staphylococcus aureus* Cytotoxicity against Bacterial Isolates Collected from Mechanically Ventilated Patients

1533. The Use of QuantiFERON®-CMV Gamma Interferon-releasing Assay as a Diagnostic Stewardship Tool following Kidney Transplantation

2185. Trend of Multidrug-Resistant Pathogens in a Burn Center during a 6-year Period: A Single Burn Center Study in South Korea

2190. Assessing Case Definition During a Hepatitis A Outbreak — San Diego County, 2017–2018

IDWeek Poster Discussion Rounds

IDWeek Poster Discussion Rounds will take place from 12:30 – 1:45 p.m. in the following areas:

IDExpo Hall – Area A

Thursday, October 4

73. *Clostridium difficile*

Friday, October 5

152. Healthcare Epidemiology

Saturday, October 6

256. Clinical Trials

IDExpo Hall – Area B

Thursday, October 4

72. Antiretroviral Therapy

Friday, October 5

153. PrEP

Saturday, October 6

257. Diagnostics

IDExpo Hall – Area C

Thursday, October 4

73. Antimicrobial Resistance

Friday, October 5

154. Novel Agents


Saturday, October 6

262. Co-morbidities and Metabolic Disorders

IDExpo Hall – Area D

Saturday, October 6

259. Immunocompromised Hosts





The Infectious Diseases Society of America (IDSA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Credit Designation Statement

IDSA designates this live activity for a maximum of 35.5 *AMA PRA Category 1 Credits*™. The core IDWeek sessions are designated for 23.5 credit hours and premeeting workshops are an additional 12. Physicians should only claim credit commensurate with the extent of their participation in the activity. **The deadline to claim credit is Monday, November 26, 2018.**

American Board of Internal Medicine MOC

All CME accredited sessions are also available for attendees to earn American Board of ABIM MOC points.

Successful completion of this CME activity enables the participant to earn up to 23.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. More MOC points can be earned through pre-meeting workshops for an additional fee.

IDWeek 2018 physician participation information will be shared with ABIM through ACCME PARS.

American Board of Pediatrics MOC

There are 30 sessions available for attendees to earn ABP MOC points. Attendees may earn a total of 15 MOC points and must attend 10-15 of the 30 sessions.

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 15 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

IDWeek 2018 physician participation information will be shared with ABP through ACCME PARS.

The continuing education activities for pharmacists have been developed through a joint providership of ProCE, Inc. and the Infectious Diseases Society of America (IDSA). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-18-178-L01-P through 0221-9999-18-281-L04-P, and 0221-9999-18-301-L01-P through 0221-9999-18-316-L01-P have been assigned to these live knowledge-based and application-based sessions (initial release date October 2-7, 2018). This conference is acceptable for up to 34.6 contact hours (3.46 CEUs) in states that recognize ACPE providers. The registration fee covers the cost of CE credits. CE Statements will be issued by the Infectious Diseases Society of America (IDSA) at the conclusion of the conference. Participants must complete an evaluation for each session they attended to receive pharmacy CE credit. The deadline for completing the evaluations is **Monday, November 26, 2018.**

